Table 6.

Sensitivity analysis for other-cause death with different HRs relative to U.S. life tables

Recurrence in 5 yearsRecurrence in 5–10 years
HRPercentage with PSA recurrenceLower bound on percent overdetectedPercentage with PSA recurrenceLower bound on percent overdetected
1.013.0 (12.4–13.7)20.2 (18.0–22.5)5.1 (4.7–5.6)31.4 (27.3–35.5)
0.913.1 (12.4–13.7)18.7 (16.6–20.8)5.2 (4.8–5.6)29.2 (25.3–33.0)
0.813.1 (12.5–13.8)16.7 (14.7–18.7)5.4 (4.9–5.8)28.1 (24.4–31.9)
0.713.2 (12.5–13.8)15.4 (13.5–17.3)5.4 (5.0–5.9)25.3 (21.7–28.9)
0.613.3 (12.6–13.9)13.1 (11.3–15.0)5.5 (5.0–5.9)22.6 (19.2–26.1)
0.513.3 (12.7–14.0)11.4 (9.7–13.2)5.6 (5.1–6.1)19.4 (16.3–22.5)
0.413.3 (12.7–14.0)9.1 (7.6–10.6)5.7 (5.3–6.2)15.6 (12.6–18.5)
0.313.5 (12.8–14.1)7.0 (5.7–8.4)5.8 (5.3–6.2)11.9 (9.3–14.5)
0.213.5(12.8–14.2)4.8 (3.6–6.0)5.9 (5.5–6.4)7.9 (5.7–10.1)
0.113.6 (12.9–14.2)2.4 (2.0–3.2)6.1 (5.6–6.5)4.7 (3.0–6.4)

NOTE: HR for risk of metastasis is as estimated from JHU untreated PSA-recurrent cohort.